REGENXBIO Inc. (RGNX)
REGENXBIO Inc. develops gene therapies to treat rare diseases and retinal disorders using its NAV Technology Platform. Its pipeline includes treatments for conditions like wet AMD and Duchenne muscular dystrophy, with partnerships fueling growth and innovation. Chart
Nuvectis Pharma, Inc. (NVCT)
Nuvectis Pharma focuses on oncology therapeutics targeting difficult-to-treat cancers. Its lead candidate NXP800 is in clinical development, aimed at improving outcomes in ovarian and other solid tumors, with innovation and unmet need driving momentum. Chart
Abeona Therapeutics Inc. (ABEO)
Abeona Therapeutics is advancing cell and gene therapies for rare and life-threatening diseases. With EB-101 for recessive dystrophic epidermolysis bullosa nearing approval, and robust pipeline support, the company is positioned for pivotal growth. Chart